Test Price
650 AED✅ Home Collection Available
t(4;11)(q21;q23) [MLL-AF4] Fusion Transcript PCR Qualitative Test in UAE | 650 AED | Molecular Genetic Analysis
Executive Summary & Core Metrics
This advanced molecular genetic assay delivers qualitative detection of the t(4;11)(q21;q23) MLL-AF4 fusion transcript, the defining biomarker of high-risk acute lymphoblastic leukemia (ALL) in infants and adults. Performed under ISO 9001:2015 certified protocols, the test achieves a clinical sensitivity of 99.9% with the ability to detect one leukemic cell among 10,000 normal cells. Hospital-based bone marrow aspiration is required for specimen collection. Results are typically available within 48–72 hours, accompanied by telephonic clinical consultation for result interpretation. Insurance pre-authorization support is available via WhatsApp at +971545488731.
Test Overview & Methodology
The qualitative real-time polymerase chain reaction (qPCR) assay specifically identifies the MLL-AF4 fusion transcript resulting from the balanced translocation between chromosomes 4 and 11. This molecular rearrangement is a hallmark of high-risk ALL and carries critical prognostic and therapeutic implications. The method combines high analytical sensitivity with rapid turnaround, enabling early risk stratification and treatment planning.
| Parameter | Our Test (Molecular qPCR) | Conventional Cytogenetics |
|---|---|---|
| Methodology | Real-Time PCR with melt curve analysis | Karyotyping / FISH |
| Sensitivity | Detects 1 leukemic cell in 10,000 (10⁻⁴) | ~5–10% abnormal metaphases required |
| Turnaround Time | 48–72 hours; samples Mon–Thu by 11 AM | 10–14 days |
| Specimen | Bone marrow aspirate (preferred) or 3 mL whole blood EDTA | Bone marrow aspirate |
Price: 650 AED. Hospital extraction only for bone marrow specimens.
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specializing in hematologic malignancies, I confirm that the MLL-AF4 fusion transcript represents a critical molecular marker in infant ALL pathogenesis. Qualitative detection of this rearrangement provides essential prognostic stratification and guides therapeutic decision-making, including the indication for allogeneic stem cell transplantation. The result must always be integrated with complete blood count, bone marrow morphology, and flow cytometric immunophenotyping for comprehensive clinical assessment."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Patients undergoing evaluation for MLL-AF4-associated ALL should continue all prescribed therapies, including induction chemotherapy and supportive medications, unless directed otherwise by their treating hematologist. Discontinuation of therapy without medical supervision may lead to disease progression or complications. Always consult your oncologist before making any changes to your treatment regimen.
Pre-Analytical Safety & Exclusion Criteria
- Specimen Rejection: Frozen samples, clotted bone marrow, tubes without EDTA, or volume <2 mL will be rejected. Transport refrigerated at 2–8°C. Do not freeze.
- Mandatory Paperwork: Complete clinical history including CBC, blast percentage, and prior cytogenetics must accompany the requisition. Missing history will delay processing.
- Patient Red Flags: If the patient has active severe sepsis, hemodynamic instability, or suspected tumor lysis syndrome, sample collection should be deferred until clinically stable.
- Emergency Signs: Seek immediate hospital care if the patient develops fever >38.5°C, uncontrolled bleeding, seizure, or altered consciousness while awaiting results. These may indicate leukostasis or infection.
- Pediatric Protocol: For minors under 18 years, written parental consent is mandatory per Federal Decree-Law No. 4 of 2016 on Medical Liability. DHA-licensed phlebotomists follow pediatric pain management guidelines.
Patient FAQ & Clinical Guidance
1. What is the clinical significance of a positive MLL-AF4 result?
A positive result confirms the presence of the MLL-AF4 fusion transcript, which in infants and children confers an adverse prognosis and typically mandates an intensive chemotherapy backbone with consideration for allogeneic stem cell transplantation in first complete remission. The finding directly influences hematopoietic stem cell donor search and eligibility for clinical trials targeting menin-MLL interactions. In adults, the rearrangement is associated with high-risk disease and may guide similar intensification strategies.
2. Can this test be performed on peripheral blood instead of bone marrow?
Yes, peripheral blood can be used if the circulating blast percentage is adequate, which may help avoid repeated bone marrow aspiration in children. However, bone marrow remains the gold standard for initial diagnosis due to its higher cellularity and sensitivity. For minimal residual disease monitoring, paired blood and marrow samples are sometimes analyzed to determine the most sensitive matrix for each patient.
3. How should I prepare my child for bone marrow aspiration?
Bone marrow aspiration is performed under conscious sedation or general anesthesia by a qualified pediatric hematologist. Your child should fast for 6–8 hours prior to the procedure. Written informed consent is required. Post-procedure, the site may be tender for 24–48 hours; acetaminophen is typically sufficient for pain management. Contact your physician if you notice excessive bleeding, swelling, or fever after the procedure.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This laboratory strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted and processed under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Telephonic clinical guidance is provided for informational purposes and does not replace a face-to-face consultation. For insurance pre-authorization, send your Emirates ID and policy card via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | t(4;11)(q21;q23) [MLL-AF4] Fusion Transcript PCR Qualitative Test |
| Price (AED) | 650 AED |
| Turnaround Time | 48–72 hours from sample receipt; samples accepted Monday–Thursday by 11 AM |
| Sample Type / Matrix | Bone marrow aspirate (preferred) or 3 mL peripheral whole blood in lavender EDTA tube Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Qualitative Real-Time PCR (qPCR) with melt curve analysis for MLL-AF4 fusion transcript detection |
| ICD-10-CM Code | C91.00 (Acute lymphoblastic leukemia not having achieved remission) |
| LOINC Code | 92870-7 (MLL-AF4 fusion transcript [Presence] in Bone marrow by PCR) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians